Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal Cancer
Status:
Terminated
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
The objective is to compare the efficacy and safety of masitinib in combination with FOLFIRI
( irinotecan, 5-fluorouracil and folinic acid) to placebo in combination with FOLFIRI in
second line treatment of patients.